Schoepp, Darryle D.

Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo

Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 1,265

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine

Schizophrenia research and treatmentNeuroscience and Neuropharmacology Research

Cited by 1,040

Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors

Cartmell, J., & Schoepp, D. D. (2000) · Journal of Neurochemistry

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 883

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery

Neuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

Cited by 607

A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission

Clarke, V. R. J., Ballyk, B. A., Hoo, K. H., Mandelzys, A., Pellizzari, A., Bath, C. P., Thomas, J., Sharpe, E. F., Davies, C. H., Ornstein, P. L., et al. (1997) · Nature

Neuroscience and Neuropharmacology ResearchEpilepsy research and treatment

Cited by 416

Translating Glutamate: From Pathophysiology to Treatment

Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 168

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E., McKinzie, D. L., Nisenbaum, E. S., Tizzano, J. P., & Schoepp, D. D. (2005) · Psychopharmacology

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 156

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

Witkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 105

LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats

Helton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J. (1997) · Neuropharmacology

Smoking Behavior and CessationNeuroscience and Neuropharmacology Research

Cited by 103

Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic–pituitary–adrenal axis and noradrenergic function

Coplan, J. D., Mathew, S. J., Smith, E. L. P., Trost, R. C., Scharf, B. A., Martinez, J., Gorman, J. M., Monn, J. A., Schoepp, D. D., & Rosenblum, L. A. (2001) · CNS Spectrums

Stress Responses and CortisolNeuroscience and Neuropharmacology Research

Cited by 18